查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球前列腺增生市场-2022-2029
市场调查报告书
商品编码
1140745

全球前列腺增生市场-2022-2029

Global Benign Prostate Hyperplasia (BPH) Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

增加老年人口是市场增长的驱动力

良性前列腺增生 (BPH) 越来越成为老年男性日益关注的健康问题。随着老年男性人数的增加，这个问题的严重程度预计在未来几年会翻一倍。世界老年人口正在显着增加。近年来，美国的老年人口不断增加。例如，到 2020 年，大约 16.9% 的美国人口将超过 65 岁，预计到 2050 年将达到 22%。此外，美国的出生率在过去 20 年一直在下降。在美国，加利福尼亚州和佛罗里达州占主导地位。根据世界卫生组织 (WHO) 的估计，到 2030 年，六分之一的人将超过 60 岁。 60岁及以上人口比例将从2020年的10亿增加到14亿。到 2050 年，全球 60 岁及以上的人口将翻一番。从 2020 年到 2050 年，80 岁及以上的人口预计将增加两倍，达到 4.26 亿。大约一半的男性在 60 岁时发生组织病理学 BPH，90% 到 85 岁时发生。 BPH 的症状影响全球 3000 万男性和美国 1400 万男性。

此外，对前列腺癌和其他泌尿系统疾病的认识不断提高，以及全球良性前列腺增生 (BPH) 患者数量的增加，也推动了需求。

但是，与 BPH 药物相关的副作用正在阻碍市场增长。良性前列腺增生的治疗包括药物治疗和手术治疗，两者都有严重的副作用。ALPHA-受体阻滞剂、5-ARI（5-ALPHA还原□抑製剂）和其他类别的药物广泛用于治疗 BPH。头晕、体位性低血压、逆行射精和鼻炎都是ALPHA受体阻滞剂的典型副作用。头晕和直立性低血压在老年人中很常见，并导致跌倒和骨折等严重问题。与药物使用相关的并发症是预计在预测期内抑制全球市场增长的关键因素。

地理渗透率

北美将是预测期内的主要地区。

该研究按地区分析了全球市场的 BPH 市场，包括北美、欧洲、亚太地区、南美、中东和非洲。

北美将在 2021 年主导全球良性前列腺增生 (BPH) 市场。在北美，预计美国在预测期内将出现大幅增长。 BPH 和其他相关下尿路症状的高患病率。过去十年的多项研究表明，美国大量 45 至 80 岁的男性患有下尿路症状，其中大多数人出现 BPH 症状，因此，良性前列腺增生 (BPH) 市场） 很大。此外，预计美国在预测期内的价值将出现显着增长。预计对研发和先进产品开发的大量投资将推动区域市场的增长。

由于人口众多，尤其是在印度和中国，预计亚太地区良性前列腺增生 (BPH) 市场将在预测期内快速增长。此外，预计不断上涨的医疗成本和各种泌尿系统疾病患病率的激增将推动亚太地区良性前列腺增生（BPH）市场的增长。

竞争格局

由于大型医疗公司的存在，良性前列腺增生 (BPH) 市场是一个竞争激烈的市场。对全球市场增长做出贡献的主要公司有 Endo International plc、KARL STORZ GMBH &CO.KG、Lumenis、Olympus Corporation、Urologix Inc、Boston Scientific Corporation、Coloplast A/S、Lisa Laser、Medifocus Inc、Neotract Inc 等。领先公司正在为良性前列腺增生 (BPH) 市场的全球增长采用新产品发布和扩张战略。 2020 年 12 月，Endo International plc 以每股 88.50 美元的全现金交易收购了商业阶段的生物製药公司 BioSpecifics Technologies Corp.。通过此次收购，公司扩大了其 XIAFLEX 和 Qwo 产品的调整后 EBITDA 和盈利能力。这两款产品是我们最耐用、最具差异化的产品，具有显着的长期增长潜力。 2021 年 8 月，Stride Pharma 以 2400 万美元收购了总部位于美国的 Endo International plc 的子公司。通过此次收购，该公司从 Endo International plc 收购了 20 种新产品。此次收购将使 Stride Pharma 在美国的产品组合翻一番，并可能每季度推出五到六种新产品。 2022 年 8 月，Teleflex 宣布与 Fundamental VR 合作，通过虚拟现实模拟改进培训。通过此次合作，VR 培训平台和 Teleflex 加速了公司 Urolift 2 系统的有效使用，该系统是一种良性前列腺增生 (BPH) 治疗技术。

COVID-19 的影响。它对全球良性前列腺增生（BPH）市场产生了负面影响。

预计 COVID-19 流行病将对 BPH 治疗行业产生重大影响。建议推迟良性病变的择期手术，直到 COVID-19 对医疗保健系统造成压力，医院正在对服务进行大量投资，以应对 COVID-19 爆发的潜在增加。面对需求。因此，TURP、HoLEP、ThuLEP 和 PVP 等外科手术不得不推迟。

全球 BPH 市场报告提供对大约 61 个市场数据表、52 个图表和 170 页的访问。

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按药物类型划分的市场细分
  • 手术市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 促进因素
      • 老年人口增加
      • 提高对前列腺癌和其他泌尿系统疾病的认识
    • 抑制因素
      • 抑制因素：良性前列腺增生药物的副作用
    • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST 分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按药物类型

  • ALPHA 阻滞剂
  • 5-ALPHA还原□抑製剂

第 8 章外科手术

  • 防水布
  • TUMT
  • TUNA
  • 其他

第 9 章最终用户

  • 医院
  • 居家护理
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • Endo International plc
    • 公司概况
    • 药物类型组合和描述
    • 主要亮点
    • 财务摘要
  • KARL STORZ GMBH & CO.KG.
  • Lumenis
  • Olympus Corporation
  • Urologix Inc.
  • Boston Scientific Corporation
  • Coloplast A/S
  • Lisa Laser
  • Medifocus Inc.
  • Neotract Inc.（LIST NOT EXHAUSTIVE）

第 13 章重要注意事项

第 14 章 DataM

简介目录
Product Code: DMPH3158

Market Overview

Benign Prostate Hyperplasia (BPH) Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 6 % during the forecast period (2022-2029).

BPH (benign prostatic hyperplasia) is a urological disease marked by the non-cancerous proliferation of prostate gland cells. The gland enlarges due to this disease, rubbing against the urethra and limiting urine flow. Ageing, hormonal imbalances, and irregular cell growth are also related to this disease. BPH is characterized by excessive urination, trouble starting urine, a poor urinary tract, and the inability to drain the urinary bladder. Men with mild to moderate BPH are currently treated with drugs. The growth in the male geriatric population is driving the global benign prostatic hyperplasia therapeutics industry.

Market Dynamics: The rise in geriatric population drives market growth

BPH (benign prostatic hyperplasia) is becoming more commonly recognized as a growing health concern among elderly men. The magnitude of the problem is predicted to multiply in the coming years as the number of elderly men increases. The global geriatric population is growing significantly. In the past few years, the aging population of the United States increasing. For instance, in 2020, about 16.9 percent of the American population was 65 years old or over, which is expected to reach 22 percent by 2050. In addition birth rate in the United States has been falling over the last 20 years. California and Florida are the dominant states in the United States. According to World Health Organization's estimated data, by 2030, 1 in 6 people will be aged 60 years or above. The share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double. The aging population above 80 or older is expected to triple between 2020 and 2050 to reach 426 million. By the age of 60, nearly half of men have histopathologic BPH, and by the age of 85, 90% of men have it. BPH signs affect 30 million men globally and 14 million men in the United States.

Other factors driving demand development include increased awareness of prostate cancer and other urological diseases and a rise in the number of patients with benign prostatic hyperplasia worldwide.

However, the side effects associated with BPH medications hamper the market growth. Although both medications and surgery can be used to treat BPH, both have serious side effects. Alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other drug groups are widely used to treat BPH. Dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis are all typical side effects of alpha-blockers. Dizziness and orthostatic hypotension are most frequent in the elderly, leading to severe problems such as falls and fractures. The complications associated with the use of drugs are a key factor expected to curtail the growth of the global market over the forecast period.

Market Segmentation: TURP segment is projected to be the dominant segment in the market during the forecast period.

The global benign prostate hyperplasia (BPH) is segmented based on surgery, which includes TURP, TUMT, TUNA and Others.

TURP held the dominant position in the global market during the forecast period owing to the surge in TURP surgery globally. Prostate transurethral resection is a urological technique used to treat benign prostatic hyperplasia (BPH). It includes visualizing the prostate through the urethra and cutting tissue with electrocautery or sharp dissection. As a result, the demand is expected to increase as TURP becomes more common. Moreover, the TURP is expected to project a considerable CAGR during the forecast period.

Benign prostate hyperplasia (BPH) is segmented based on end-user, which includes hospitals, home care and others.

The homecare segment held a significant market share in the forecast period. The majority of patients are given drugs instead of surgery. Patients should continue taking their medications for a few weeks after surgery. As a result, the market is driven by home treatment compared to hospital services. Moreover, the demand is expected to increase with a rising preference for home care settings. Therefore, home care is expected to project a considerable CAGR during the forecast period.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the Benign Prostate Hyperplasia (BPH) market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America held a dominant position in the global benign prostate hyperplasia (BPH) market in 2021. In North America, the U.S. is expected to represent considerable growth during the forecast period. High prevalence of BPH and other associated lower urinary tract symptoms. Several studies over the past decade have shown that a large number of men in the U.S. aged 45 to 80 suffer from lower urinary tract symptoms, with the bulk of them experiencing BPH symptoms, which results in a huge market for benign prostate hyperplasia (BPH). Moreover, the United States is expected to represent significant growth in terms of value during the forecast period. Significant investment in R&D and advanced product development is expected to propel regional market growth.

The benign prostate hyperplasia (BPH) market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the large population base, especially in India and China. Moreover, the rise in health care expenditure and the rapidly increasing prevalence of various urologic diseases are expected to augment the growth of the Asia Pacific Benign Prostate Hyperplasia (BPH) market.

Competitive Landscape:

The benign prostate hyperplasia (BPH) market is highly competitive, owing to the presence of big medical companies. The key players which are contributing to the growth of the global market include Endo International plc, KARL STORZ GMBH & CO.KG, Lumenis, Olympus Corporation., Urologix Inc., Boston Scientific Corporation, Coloplast A/S, Lisa Laser, Medifocus Inc, Neotract Inc, among others. The major players are adopting new product launches and expansion strategies for global growth in the benign prostate hyperplasia (BPH) market. In December 2020, Endo International plc acquired BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction. Through this acquisition, the company expanded its adjusted EBITDA and the profitability profile of both XIAFLEX and Qwo. These two products are the most durable and differentiated products with significant long-term growth potential. In August 2021, Strides Pharma acquired arms of Endo International plc (Endo) in the U.S. for $24 million. Through this acquisition, the company acquired 20 new commercial products from Endo International plc. Through this acquisition, Strides Pharma doubled its U.S. portfolio, potentially launching 5-6 new products each quarter. In August 2022, Teleflex announced a collaboration with Fundamental VR to improve training through virtual reality simulation. Through this collaboration Teleflex with a VR training platform to accelerate the effective use of the company's UroLift 2 system, a technology for treating benign prostatic hyperplasia (BPH).

COVID-19 Impact: Negative impact on the global benign prostate hyperplasia (BPH) market.

The COVID-19 epidemic is projected to have a major effect on the BPH care industry. Elective surgeries with benign pathology were advised to be deferred until the burden on the medical system from COVID-19 lessened, so hospitals will face a tremendous need for services to tackle a potential rise in COVID-19 incidents. Surgical operations such as TURP, HoLEP, ThuLEP, and PVP had to be delayed as a result.

The global benign prostate hyperplasia (BPH) market report would provide an access to approximately 61 market data tables, 52 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market Snippet by Surgery
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in Geriatric Population
      • 4.1.1.2. Increasing awareness of prostate cancer and other urological diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. Side-effects associated with BPH medications
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 7.3. Market Attractiveness Index, By Drug Type Segment
    • 7.3.1. Alpha Blocker*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. 5-Alpha Reductase Inhibitors

8. By Surgery

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery Segment
  • 8.3. Market Attractiveness Index, By Surgery Segment
    • 8.3.1. TURP*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. TUMT
    • 8.3.3. TUNA
    • 8.3.4. Others

9. By End User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
  • 9.3. Market Attractiveness Index, By End User Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Home Care
    • 9.3.3. Others

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Endo International plc*
    • 12.1.1. Company Overview
    • 12.1.2. Drug Type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. KARL STORZ GMBH & CO.KG.
  • 12.3. Lumenis
  • 12.4. Olympus Corporation
  • 12.5. Urologix Inc.
  • 12.6. Boston Scientific Corporation
  • 12.7. Coloplast A/S
  • 12.8. Lisa Laser
  • 12.9. Medifocus Inc.
  • 12.10. Neotract Inc. (LIST NOT EXHAUSTIVE)

13. Premium Insights

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us